Loading...
Home2021-11-02T14:58:33+01:00

Parkinson’s Disease

Parkinson´s disease is a progressive neurodegenerative disorder.

The unique features of Infudopa™

Our products in development

“I have an ethical responsibility to contribute to Infudopa becoming available to patients suffering from Parkinson’s disease”

– Arvid Carlsson (1923-2018) who received the Nobel prize in 2000 for the discoveries that paved the way for the introduction of levodopa as treatment for Parkinson´s disease.

Dizlin Pharmaceuticals presented efficacy data from the IPO-001 pharmacokinetic cross-over study comparing Infudopa SubC (DIZ102), Infudopa IntraV (DIZ101), and LCIG (Duodopa) at the International Congress of Parkinson´s Disease and Movement Disorders in Copenhagen

Gothenburg, Sweden, September 13, 2023 – Dizlin Pharmaceuticals AB, a research-based pharmaceutical development company with focus on diseases of the central nervous system, has presented efficacy data from the IPO-001 pharmacokinetic cross-over study comparing Infudopa [...]

CEO Letter, Summer 2023

During the spring, Dizlin Pharmaceuticals has continued to focus on our prioritized projects: patent, pump development, preclinical pilot study, and – not least – further exchange with FDA and Swedish MPA The development program for the [...]

Dizlin Pharmaceuticals receives patent approval in the USA

Gothenburg, Sweden, April 25th, 2023 – Dizlin Pharmaceuticals AB, a research-based pharmaceutical development company with focus on diseases of the central nervous system (CNS), today announces a patent approval in the USA Dizlin Pharmaceuticals has [...]

Go to Top